Horne William B. 4
4 · Alzamend Neuro, Inc. · Filed Mar 19, 2025
Insider Transaction Report
Form 4
Horne William B
Director
Transactions
- Exercise/Conversion
Common Stock
2025-03-18$0.06/sh+10,000$600→ 16,666 total - Exercise/Conversion
Stock Options (Right to Buy)
2025-03-18−10,000→ 0 totalExercise: $0.06Exp: 2026-04-29→ Common Stock (10,000 underlying) - Purchase
Common Stock
2025-03-18$0.97/sh+5,000$4,852→ 21,666 total
Holdings
- 1,667
Stock Options (Right to Buy)
Exercise: $225.00Exp: 2029-11-25→ Common Stock (1,667 underlying) - 1,667
Stock Options (Right to Buy)
Exercise: $225.00Exp: 2029-11-17→ Common Stock (1,667 underlying)
Footnotes (5)
- [F1]This transaction was effected pursuant to Rule 16b-3 with shares of common stock received upon the exercise of stock options.
- [F2]The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $0.9703. The range of purchase prices on the transaction date was $0.9693 to $0.9742 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.
- [F3]The stock options exercised in this transaction were fully vested and exercisable as of the transaction date.
- [F4]The stock options vest ratably over thirty-six (36) months beginning on the date of grant and are fully vested.
- [F5]None of these performance-based stock options are vested or exercisable.